Navigation Links
Hyderabad To Have Asia’s First Catheter Making Uni

Hyderabad capital of Andhra Pradesh is set to house Asia's first catheter manufacturing facility, which will not only bring down the cost of catheter// based disposables but could also become an outsourcing hub for multinational companies.

Relisys Medical Devices Limited, a seven-year old company, Tuesday announced that the facility would be ready by December. Trial production is slated to begin by January next year.

The Rs.80 million facility, coming up at Manglapalli village in neighbouring Ranga Reddy district, will have the capacity to produce half a million catheter-based products annually.

To be developed as per US Food and Drug Administration (FDA) norms, it will produce 150,000 to 200,000 diagnostic catheters and 60,000 to 70,000 interventional catheters, used to pass stents to cardiac arteries.

N. Krishna Reddy, cardiologist and chairperson of Relisys, told reporters that Andhra Bank had come forward to extend a term loan of Rs.45 million for the facility.

He later told IANS that the facility would be a big boost to development of medical devices in a country, which presently produces only IV sets. "From the lowest level we are jumping to the sixth level," he said.

Krishna Reddy hoped the facility would cut the prices of catheters by 50 to 70 percent. India imports catheters at prices ranging from Rs.400 to Rs.3,000.

"This facility can not only cater to the region but also become an outsourcing hub for MNCs," he said.

The company also announced the launching of international multi-centre clinical trials of the new version of drug eluting cobalt-chromium stent coated with porous carbon-carbon nano-matrix.

Clinical trials would be conducted at nine centres in India as well as in Brazil, South Korea, Italy and Japan. The company has entered into a worldwide licensing agreement with Blue Membranes GmbH, Germany, for carbon-based drug delivery platform.

The use of porous carbon-carbon nano particle coating will eliminate the use of polymer based platform, thus completely reducing tissue inflammation and reaction (in cardiac arteries).

"Blue-Membranes will enforce the collaboration with Relisys that enables us to exploit our drug-delivery technology. We also aim to integrate manufacturing capabilities of Relisys to provide high quality manufacturing services for integrated solutions," said Soheil Asgari, CEO of Blue-Membranes.

Animal trials of this version of advanced drug eluting stent were recently completed at the Cardiovascular Research Institute, Washington.

The company had earlier completed clinical trials for its first generation drug eluting stent at All India Institute of Medical Sciences, New Delhi, Military Hospital, Pune, and Care Hospital, Hyderabad. More than 500 stents have been used since evaluation was completed six months ago.

Source: IANS


'"/>




Related medicine news :

1. Hyderabad Firm To Manufacture Tamiflu In India
2. Biotechnology Initiatives Planned In Hyderabad
3. US Consulate to Start Hyderabad Operations Next Year
4. First Vaccine Designed for Africa Cleared for Testing in Humans
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. First human clone is near
7. First Artificial Heart patient has Major setback
8. First head-to-head trials of once weekly Fosamax and Actonel therapies
9. WHO Declares Vietnam First Country to Control SARS
10. Russia Reports First SARS Case
11. Hope for First New Melanoma Treatment in Decades
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science ... evaluation leaders with decades of experience who remain current practitioners in the field. ... system, there is a renewed demand for versatile, data-driven leadership.The American University’s MS ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a ... method is paramount to success. Selecting an inappropriate measurement method can cause costly ... use the same equipment. Rare or expensive substances are wasted and production may ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of ... gynecological services for women of all ages. The staff of Gynecology ... of reproductive services from routine health screenings to diagnosing and treating female concerns ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan 23, 2017 Research and Markets has announced ... Trends - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... market trends to identify the investment opportunities Market forecasts ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
(Date:1/23/2017)... January 23, 2017 Ahead of today,s trading ... how they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... were relative laggards on Friday, January 20 th , 2017, down ... research reports on these stocks now at: ...
Breaking Medicine Technology: